KU 2285: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 366729 |
| SCHEMBL ID | 9716538 |
| MeSH ID | M0189167 |
| Synonym |
|---|
| nsc-635446 |
| nsc635446 |
| 1h-imidazole-1-propanamide, alpha,alpha-difluoro-n-(2-hydroxyethyl)-2-nitro- |
| alpha,alpha-difluoro-n-(2-hydroxyethyl)-2-nitro-1h-imidazole-1-propionamide |
| ku-2285 |
| ku 2285 |
| 1h-imidazole-1-propionamide, alpha,alpha-difluoro-n-(2-hydroxyethyl)-2-nitro- |
| 2,2-difluoro-n-(2-hydroxyethyl)-3-(2-nitro-1h-imidazol-1-yl)propanamide |
| 121077-11-0 |
| 2,2-difluoro-n-(2-hydroxyethyl)-3-(2-nitroimidazol-1-yl)propanamide |
| doc00vd5vl , |
| unii-doc00vd5vl |
| 1h-imidazole-1-propanamide, .alpha.,.alpha.-difluoro-n-(2-hydroxyethyl)-2-nitro- |
| SCHEMBL9716538 |
| nsc 635446 |
| voxufopzgrtsjy-uhfffaoysa-n |
| Q27276509 |
| imidazole,2-nitro-1-(3-hydroxyethylamino-3-oxo-2 |
| DTXSID40879131 |
| AKOS040752286 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "01) less toxic than RK-28 at this dose, as reflected in a lower increase in the brain glucose level (0." | ( Metabolic studies and neurotoxicity in tumors and brain of mice after hypoxic cell sensitizers. Streffer, C; Tamulevicius, P, 1994) | 0.29 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic studies were performed in C3H/He mice bearing the SCCVII tumor." | ( Fluorinated 2-nitroimidazole derivative hypoxic cell radiosensitizers: radiosensitizing activities and pharmacokinetics. Abe, M; Iwai, H; Nishimoto, S; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Yoshizawa, T, 1994) | 0.29 |
| " Evaluation of pharmacokinetics in the peripheral nerves showed that the apparent biological half-life of SR-2508 increased with the increases in the number of administrations, whereas that of KU-2285 became shorter." | ( Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice. Abe, M; Iwai, H; Matsuno, E; Sasai, K; Shibamoto, Y, 1994) | 0.29 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Since most clinical radiotherapy is given as multiple small irradiation fractions, the present study was undertaken to test the in vivo radiosensitizing activity of a new hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation." | ( In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation. Abe, M; Fushiki, M; Iwai, H; Nishimoto, S; Sasai, K; Shibamoto, Y; Suyama, S; Takahashi, M; Yukawa, Y, 1991) | 0.28 |
| " In the present study, the in vivo effects of a promising hypoxic cytotoxin, tirapazamine (3-amino-1,2,4-benzotriazine 1,4-di-N-oxide), were examined in comparison with those of KU-2285, one of the best hypoxic cell radiosensitizers, in combination with both single and fractionated irradiation." | ( Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation. Abe, M; Hiraoka, M; Murata, R; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Takagi, T, 1996) | 0.29 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, the in vivo radiosensitizing activity of KU-2285 in combination with radiation dose fractionation, and the pharmacokinetics of cumulative dosing of KU-2285 in the peripheral nerves were examined." | ( Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice. Abe, M; Iwai, H; Matsuno, E; Sasai, K; Shibamoto, Y, 1994) | 0.29 |
| " The radiation dose-response curves of MN frequency suggested that the interaction of tirapazamine with irradiation appeared to be essentially additive in both cell lines." | ( Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay. Abe, M; Hiraoka, M; Murata, R; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Takagi, T; Takahashi, M, 1996) | 0.29 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (89.47) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (10.53%) | 5.53% |
| Reviews | 1 (5.26%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (84.21%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||